Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1994-12-08
1997-07-15
Mosher, Mary E.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4242311, 935 65, A61K 39245
Patent
active
056480792
ABSTRACT:
The glycoprotein B ("gB") and analogs thereof are provided by recombinant DNA technology. Oligonucleotide sequences are provided coding the glycoprotein, its precursor and fragments thereof. Methods and compositions are disclosed for the production of the glycoprotein and analogous proteins as well as oligonucleotide sequences, which may be used for probes or other applications, and particularly may be used for vaccines.
REFERENCES:
patent: 4172125 (1979-10-01), Audibert et al.
patent: 4317811 (1982-03-01), Bertland et al.
patent: 4374127 (1983-02-01), Larson et al.
patent: 4642333 (1987-02-01), Person
patent: 4661349 (1987-04-01), Kino et al.
patent: 4724146 (1988-02-01), Kino et al.
patent: 5171568 (1992-12-01), Burke et al.
Straus, S.E. et al. 1985. Annals of Internal Medicine, vol. 103, pp. 404-419.
Stanberry, L. R. et al. 1989. Journal of General Virology, vol. 70, pp. 3177-3185.
Byars, N.E. et al. 1994. Vaccine, vol. 12, pp. 200-209.
Sanchez-Pescador, L. et al. 1988. Journal of Immunology, vol. 141, pp. 1720-1727.
Burke, R.L. et al. 1994. Journal of Infectious Disease, vol. 170, pp. 1110-1119.
Dix et al, J. Med. Vir. 17:9-18, 1985.
Gething et al., "Cell-surface expression of influenze haemagglutinin from a cloned DNA copy of the RNA gene," Nature 293:620-625 (1981).
Rose, "Expression from cloned cDNA of cell-surface secreted forms of the glycoprotein of vesicular stomatitis virus in eucaryotic cells," Cell 30:753-762 (1982).
Sveda et al., "Cell surface expression of the influenza virus hemagglutinin requires the hydrophobic carboxy-terminal sequences," Cell 30:649-656 (1982).
Zoler et al., "Scientists engineer proteins for cellular export," Bio/Technology:146-147 (1983).
Berman et al., Science (1985) 227:1490-1492.
Bzik et al., Virology (1984) 133:301-314.
Cappel et al., J. Med. Virol. (1985) 16:137-145.
Chan, Immunology (1983) 49:343-352.
Cohen et al., J. Virol. (1984) 49:102-108.
DeLucca et al., Virology (1982) 122:411-423.
Dundarov et al., Devel. Biol. Standard. (1982) 52:351-357.
Eberle et al., J. Infect. Dis. (1983) 148:436-444.
Hilfenhaus et al., Devel. Biol. Standard. (1982) 52:321-331.
Lasky et al., Biotechnology (Jun. 1984) pp. 527-532.
Marsden et al., J. Virol. (1978) 28:624-642.
Pellet et al., J. Virol. (1985) 53:243-253.
Roizman et al., Ann. Rev. Genet. (1979) 13:25-57.
Ruyechan et al., J. Virol. (1979) 29:677-697.
Skare et al., Virology (1977) 76:581-595.
Skinner et al., Devel. Biol. Standard. (1982) 52:333-344.
Watson et al., Science (1982) 218:381-384; and.
Weis et al., Nature (1983) 302:72-74.
Burke Rae L.
Pachl Carol
Valenzuela Pablo D. T.
Blackburn Robert P.
Chiron Corporation
McClung Barbara G.
Mosher Mary E.
Robins Roberta L.
LandOfFree
Herpes simplex virus glycoprotein B vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Herpes simplex virus glycoprotein B vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Herpes simplex virus glycoprotein B vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1490884